+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease



Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease



Best Practice and Research. Clinical Gastroenterology 28(3): 437-449



The recent success of the anti-integrin antibody Vedolizumab can barely conceal the fact that the biologics armamentarium in Crohn's disease has barely evolved beyond TNF blockers so far. This contrasts with other immune-related diseases considered mechanistically and genetically closely related, such as psoriasis and rheumatoid arthritis, where approved biologics target a variety of independent biological mechanisms. Several pharmacological assets that entered clinical development have proven ineffective, or less effective than originally anticipated. While blockade of IL-17A and its receptor via Secukinumab and Brodalumab, respectively, worsened Crohn's disease, the beneficial effect of IL-12/23 p40 blockade via Ustekinumab appeared confined to a subpopulation of Crohn's disease patients who have previously failed on TNF blockers. Clinical development of the IFNγ blocker Fontolizumab was stopped despite demonstrating some clinical benefit, while the T cell co-stimulation blocker Abatacept did not exhibit any hint towards efficacy in Crohn's disease. Here I review results from these individual development programmes, and also reflect on the lack of efficacy of the TNF blocker Etanercept. I will discuss aspects of individual trials that might have confounded their interpretation and highlight the evolution in primary and secondary endpoints that have contributed to increasing robustness of results obtained in recent years. Finally, I suggest that mechanistic studies in murine genetic models combined with exploratory immunological studies incorporated in early drug development may represent the key for identifying the next generation of successful pharmacological targets in Crohn's disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 054661213

Download citation: RISBibTeXText

PMID: 24913383

DOI: 10.1016/j.bpg.2014.04.005


Related references

Not all RCTs are created equal: lessons from early AIDS trials. American Journal of Bioethics 15(4): 45-47, 2015

Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American Heart Journal 151(2): 273-281, 2006

What lessons can be learned from failed Alzheimer's disease trials?. Expert Review of Clinical Pharmacology 8(3): 267-269, 2015

Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions. Journal of Alzheimer's Disease 15(2): 327-338, 2008

Monoclonals against TNF are a major advance in the treatment of Crohn's disease. New Zealand Medical Journal 127(1396): 10-14, 2014

All clinical trials are not created equal: The dilemma of HEAAL. European Journal of Heart Failure 10(9): 817-818, 2008

Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis. Current Drug Targets 12(10): 1467-1477, 2012

Infliximab in drug-naïve patients with failed ileorectal anastomosis for Crohn's disease: a new chance for sparing the rectum?. European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes 46(4): 163-168, 2011

Drug response: all bodies are not created equal. American Journal of Nursing 92(12): 48-50, 1992

Lessons from the past: failed MS trials. International Ms Journal 14(1): 3-4, 2007

The relation between NOD2/CARD15 mutations and the prevalence and phenotypic heterogeneity of Crohn's disease: lessons from the Israeli Arab Crohn's disease cohort. Digestive Diseases and Sciences 50(9): 1692-1697, 2005

All PUFAs are not created equal: absence of CHD benefit specific to linoleic acid in randomized controlled trials and prospective observational cohorts. World Review of Nutrition and Dietetics 102: 30-43, 2012

The success rate of new drug development in clinical trials: Crohn's disease. Journal of Pharmacy and Pharmaceutical Sciences 13(2): 191-197, 2010

Lessons from failed trials a community response. Morisset, R A (Ed ) Ve Conference Internationale Sur Le Sida: Le Defi Scientifique Et Social; V International Conference on Aids: The Scientific And Social Challenge; Montreal, Quebec, Canada, June 4-9, 1262p International Development Research Centre: Ottawa, Ontario, Canada Illus Paper 917, 1989

Is all chronic kidney disease created equal?. Current Opinion in Urology 24(2): 127-134, 2014